Tirzepatide

Pack of 10 × 30mg powder vials in a protective case

Enlarge

Choose strength

5mg × 10 vials 10mg × 10 vials 15mg × 10 vials 20mg × 10 vials 30mg × 10 vials 40mg × 10 vials 50mg × 10 vials 60mg × 10 vials 70mg × 10 vials 80mg × 10 vials 90mg × 10 vials 100mg × 10 vials 110mg × 10 vials 120mg × 10 vials

Price · per pack

£245.00

Available to order

£345.00 Save £100.00 (29%)

£24.50 per vial · 10 vials per case

Free delivery £50+ Royal Mail Tracked 24

Approx. 2-week lead time. Dispatch follows availability.

Batch documentation

COA not yet available. Ask about documentation →

Explore research & studies

Product overview & specifications

Tirzepatide in 10-vial case. Check the product record for the stated strength, storage information and batch-document availability.

Strength: 30mg × 10 vials
Presentation: 10-vial case
Batch documentation: availability shown on this listing

Strength30mg × 10 vials

Presentation10-vial case

Purity99%+

Storage2-8 C

Part number: TR30-10PK
Storage: Store refrigerated at 2-8 C, protected from light.
COA: Added to your account when available
Delivery: Royal Mail Tracked 24 is £4.95, or free on merchandise subtotals of £50+; Approx. 2-week lead time
Tracking: Emailed once dispatched and shown in your profile
Contents: 10-vial case
Status: Research use only

For laboratory research only

For laboratory research use only. Not for human or veterinary use. No use instructions or medical guidance is provided. Understand COA documentation.

Research information

Tirzepatide research profile

What is being studied?

Tirzepatide (LY3298176) is a fatty-acid-modified peptide engineered for agonist activity at the GIP and GLP-1 receptors. The dual-receptor design provides a defined comparator for studies of selective GLP-1R agonism, selective GIPR agonism and combined incretin-receptor signalling.

Discovery studies characterised receptor activation in recombinant and endogenous cell systems, including signalling and functional assays. Further preclinical work has examined the contribution of GIPR activity to the compound's molecular profile. Findings depend on receptor expression, assay design and experimental model.

Research areas

GIPR and GLP-1R binding, potency and cAMP-response assays
Dual- versus single-receptor agonist comparison
Receptor contribution and pathway-interaction studies

Selected studies

Cell, animal and phase 1 research · 2018
LY3298176 discovery and receptor pharmacology ↗
Combined receptor assays and mouse experiments with an early clinical study of investigational LY3298176.
Animal study · 2021
GIPR agonism in preclinical tirzepatide models ↗
Investigated the contribution of GIP-receptor activity in obese mouse models.

How to read this research

These papers study defined compounds in specific experimental systems or clinical trials. They do not test or certify this product, its batch or its prepared presentation. Component and related-peptide studies do not establish the effects of a finished blend. Findings are research context, not evidence of safety or suitability for personal use. For laboratory research only; no treatment, dosing or use advice is provided.

Technical product record

Tirzepatide research record

Molecular identity and stated sequence or composition, alongside the batch, storage, dispatch and document record for this 10-vial case.

Molecular identity

Fatty-acid-modified dual incretin-receptor agonist

Sequence / composition

Engineered peptide agonist of GIPR and GLP-1R

Product record

The listing identifies the presentation, specification, storage record, dispatch status, and batch-document availability for the relevant product or batch.

Use restriction

For laboratory research use only. Not for human or veterinary consumption. No use instructions or therapeutic guidance is provided.